Selective autophagy of NLRC5 promotes immune evasion of endometrial cancer

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Endometrial cancer (EC) often shows resistance to chemotherapy, especially in advanced or recurrent stages.
• Immunotherapy presents a promising treatment avenue for advanced or recurrent EC.
• NLRC5 (NLR family CARD domain containing 5) is crucial for MHC-I antigen presentation and its absence contributes to immune evasion in cancer.

Purpose of the Study:

• To investigate the role of autophagy in regulating NLRC5 and its impact on immune evasion in endometrial cancer.
• To elucidate the interaction between autophagy protein LC3 and NLRC5 in EC.
• To identify potential immunotherapy targets for EC by understanding the NLRC5-autophagy pathway.

Main Methods:

• In vitro studies to assess the effect of autophagy on NLRC5 and MHC-I gene expression.
• In vivo studies to confirm the interaction between LC3 and NLRC5.
• Analysis of NLRC5 downregulation in EC patients.

Main Results:

• Autophagy was found to inhibit NLRC5 and NLRC5-mediated MHC-I gene expression in vitro.
• The autophagy protein MAP1LC3/LC3 directly interacts with NLRC5, inhibiting the NLRC5-mediated MHC-I antigen presentation pathway in vitro and in vivo.
• NLRC5 downregulation was observed in EC patients, indicating its role in immune evasion.

Conclusions:

• Autophagy protein LC3 plays a novel role in regulating NLRC5-mediated MHC-I antigen presentation in EC through direct interaction.
• This interaction represents a mechanism of immune evasion by autophagy in EC.
• Inhibiting LC3 and promoting NLRC5 presents a potential immunotherapy strategy for EC patients.